Our Blog

The use of real world data in clinical trials is a hot topic. Doctors, biotech and pharmaceutical companies alike point to the tremendous potential to leverage this data to improve health outcomes.

Virtual clinical trials aren’t just a buzzword—these research models are here to stay. In fact, the global market for virtual clinical trials is expected to reach $12.9 billion by 2030, according to Grand View Research.

Capturing and assessing patient-reported outcomes is key to driving patient centricity in healthcare research and delivery. However, the life sciences industry has frequently struggled to gather adequate, high-quality participant data in clinical trials, resulting in costly delays for study teams.

In this post, we provide a comprehensive breakdown of the key challenges and opportunities associated with virtual clinical trials, examining the nuances of virtual components and how their implementation might affect each stage and touchpoint of the clinical trial journey.

Clinical trial sponsors are constantly seeking ways to collect better data, faster—accelerating clinical trials. Meanwhile, patients are increasingly likely to access healthcare services and interact with healthcare professionals digitally. Growing usage of telehealth also impacts patients’ expectations of clinical trials, with convenience and accessibility taking center stage.